Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer

Published:2003-10 Issue:1 Volume:42 Page:97-102
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Hoang Tien,Kim KyungMann,Jaslowski Anthony,Koch Paul,Beatty Peter,McGovern James,Quisumbing Maria,Shapiro Gary,Witte Robert,Schiller Joan H.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference18 articles.

1. Randomized trial of cyclophosphamide, doxorubicin, and vincristin versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer;Fukuoka;J. Natl. Cancer Inst.,1991

2. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study;Goodman;J. Clin. Oncol.,1990

3. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104;Takada;J. Clin. Oncol.,2002

4. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593—a phase III trial of the Eastern Cooperative Oncology Group;Schiller;J. Clin. Oncol.,2001

5. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer;Noda;New Engl. J. Med.,2002

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer;Current Oncology;2023-06-30

2. Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis;Molecular Therapy;2022-11

3. Augmented therapeutic efficacy of Gemcitabine conjugated self-assembled nanoparticles for cancer chemotherapy;Journal of Drug Delivery Science and Technology;2022-10

4. New perspectives in the management of small cell lung cancer;World Journal of Clinical Oncology;2022-06-24

5. Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review;Cancers;2022-05-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3